

Correlation of metabolic factors with endometrial atypical hyperplasia and endometrial cancer: development and assessment of a new predictive nomogram

He Zhang (✉ zhanghe54321@ccmu.edu.cn)

Capital Medical University Beijing Obstetrics and Gynecology Hospital

Weimin Kong

Capital Medical University Beijing Obstetrics and Gynecology Hospital

Chao Han

Capital Medical University Beijing Obstetrics and Gynecology Hospital

Tingting Liu

Capital Medical University Beijing Obstetrics and Gynecology Hospital

Jing Li

Capital Medical University Beijing Obstetrics and Gynecology Hospital <https://orcid.org/0000-0002-8118-9014>

Dan Song

Capital Medical University Beijing Obstetrics and Gynecology Hospital

Research Article

Keywords: metabolic factors, endometrial cancer, endometrial atypical hyperplasia, predictors, nomogram

Posted Date: June 1st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-169940/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose: This study aimed to investigate the association of metabolic factors with endometrial atypical hyperplasia and endometrial cancer, and to develop a Nomogram model to predict the risk of developing endometrial cancer.

Patients and methods: A total of 205 patients with 102 cases of endometrial atypical hyperplasia and 103 cases of endometrial carcinoma treated by the Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, from January 1, 2010, to December 31, 2015 were collected as the study group. And 205 patients with simple endometrial hyperplasia or polyp hyperplasia in the same period were selected as the control group using age-matched method. Laboratory results of metabolic factors such as blood pressure (BP), glucose (GLU), triglycerides (TC), and high-density lipoprotein (HDL) were retrieved from the clinical data of two groups of patients. Multivariable logistic regression analysis was used to determine the risk factors associated with endometrial malignant hyperplasia and to develop a nomogram prediction model of risk factors associated with endometrial malignant hyperplasia. Discrimination, calibration, and clinical usefulness of the predicting model were assessed using the C-index, calibration plot, and decision curve analysis. Internal validation was assessed using the bootstrapping validation.

Results: Predictors included in the Nomogram prediction model included hypertension, diabetes, BMI, uric acid, hyperlipidemia and CA199. The model had a C-index of 0.782 (95% confidence interval 0.738-0.826) with good discrimination and good calibration. A high C-index value of 0.771 could still be reached in the interval validation. Decision curve analysis showed that it is meaningful to use this Nomogram for patient interventions when the threshold probability is within 22-86%.

Conclusion: The development of endometrial malignant hyperplasia is significantly associated with metabolic factors. BMI>25, hyperuricemia, and hyperlipidemia are the main risk factors for the development of endometrial malignant hyperplasia. Hypertension, hyperglycemia and elevated CA199 were also associated with the development of endometrial malignant hyperplasia in our study. The Nomogram prediction model based on physical examination and laboratory testing developed in this study can be used as a rapid method for predicting the risk of endometrial malignancy development and screening for risk factors in a population of women with metabolism-related high-risk factors.

Introduction

Endometrial cancer is one of the most common gynecological malignancies. The latest cancer statistics from the American Cancer Society showed that in 2020, the number of new cases of endometrial cancer in the United States was 65,620, and the number of deaths was 12,590. The incidence of malignant endometrial tumors in women ranked fourth, and the incidence of death from endometrial cancer ranked sixth^[1]. Endometrial atypical hyperplasia (EAH) is a precancerous lesion of endometrial cancer^[2]. The mechanisms of endometrial cancer and endometrial atypical hyperplasia pathological process are

complex and polycentric in time and space. In recent years, the development of early diagnostic surgery and radiotherapy has improved patient outcomes to a great extent. However, the diagnosis and treatment of endometrial lesions at an early stage, surgery to preserve reproductive function, and research into the treatment of advanced and recurrent patients remain promising.

Metabolic syndrome (MS) is defined as a complex of metabolic risk factors associated with a variety of diseases, including cardiovascular disease and diabetes^[3]. The main components of metabolic syndrome are obesity, diabetes or impaired glucose tolerance, dyslipidemia, and hypertension. Besides, metabolic syndrome includes insulin resistance, hyperuricemia, and microalbuminuria. Recent studies have found that the incidence of endometrial cancer is increasing with the rise in the prevalence of metabolic diseases (e.g., obesity, hypertension, diabetes, etc.)^[4]. To this end, we collected case data from the Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, to retrospectively analyze metabolic parameters in patients with endometrial hyperplasia and malignant lesions, evaluate relevant metabolic risk factors for the development of endometrial malignant hyperplasia and establish a Nomogram prediction model to predict the risk of endometrial malignant hyperplasia.

Patients And Methods

Patients

Research approval was obtained from Beijing Obstetrics and Gynecology Hospital, Capital Medical University's Ethics Committee (approval no 2021-KY-050-01). A total of 205 patients with 102 cases of endometrial atypical hyperplasia and 103 cases of endometrial carcinoma admitted to the Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, from January 1, 2010 to December 31, 2015, were collected as the study group. Considering that changes in metabolic parameters such as hypertension may be related to age or atypicality, we paired patients in the study group 1:1 with those in the control group. The control group was randomly selected from a cohort of patients suffering from simple hyperplasia or polypoid hyperplasia of the endometrium during the same period. The age difference of patients between each pairing was no more than 3 years. All patients were diagnosed with endometrioid adenocarcinoma, endometrial atypical hyperplasia, simple hyperplasia, or polypoid hyperplasia. They voluntarily signed informed consent for the study before registration, had good compliance, and were willing to closely cooperate with relevant examinations and follow-up. Patients with tumors in combination with other sites or who developed distant metastases were excluded. Patients using oral contraceptives or hormonal therapy were excluded because of their potential impact on metabolic levels. We also excluded patients with incomplete laboratory results or poor compliance.

An endometrial biopsy was performed on the patient after a thorough history of their complete medical condition and physical examination. Indications for endometrial biopsy include abnormal uterine bleeding, endometrial thickening, and cavity occupancy^[5, 6]. Before the endometrial biopsy, transvaginal

ultrasound was used to measure the thickness of the patient's endometrium. After sampling, the specimens were placed in formalin and histopathological examination was performed.

Histopathological analysis

Patients were divided into two groups based on the results of endometrial biopsies. The case group (205 cases) was diagnosed with endometrial atypical hyperplasia (102 cases) or endometrial carcinoma (103 cases). The control group (205 cases) was diagnosed with endometrial simple hyperplasia or polypoid hyperplasia. The endometrium in both the secretory and proliferative phases, atrophic endometrium, endometrial polyps, and epithelial fragments containing mucus-like material were considered normal endometrium.

Clinical and biochemical measurements

The metabolic syndrome was diagnosed under the WHO definition, when the participants presented with diabetes or impaired fasting glycemia or impaired glucose tolerance or insulin resistance, and 2 or more of 5 risk determinants: obesity (BMI > 30 or waist-to-hip ratio > 0.85), dyslipidemia (triglycerides \geq 1.7 mmol/L or HDL cholesterol < 1.0 mmol/L), hypertension (blood pressure > 140/90 mm Hg. Also, we used the ATP III cut-off values for total cholesterol (240 mg/dL for TC) and low-density lipoprotein cholesterol (160 mg/dL for LDL), above which levels are considered high. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters, and overweight was defined as a BMI of 25 or greater.

Statistical analysis

All statistical analysis was carried out using R software. (version 4.0.2; [https:// www.R-project.org](https://www.R-project.org)). Normally distributed variables were tested using independent samples t-test. The χ^2 test was used for categorical variables. Single-factor and multifactor logistic regression analysis was used to calculate the odds ratio (OR) and its 95% confidence interval (CI) to estimate the correlation effect and correlation between each factor and endometrial pathology, and to establish a Nomogram prediction model. $p < 0.05$ risk factors and some recognized risk factors associated with lesions were included in this in the model. All p-values are two-tailed and $p < 0.05$ is considered statistically significant.

Results

Patients' characteristics

A total of 410 patients with postoperative pathological findings confirming endometrioid adenocarcinoma, endometrial atypical hyperplasia, benign endometrial hyperplasia, or polypoid hyperplasia were included in this study, including 205 cases (50.0%) of endometrioid adenocarcinoma and endometrial atypical hyperplasia and 205 cases (50.0%) of benign endometrial hyperplasia or polypoid hyperplasia. The mean age of the study group was 49.4 years, 150 cases (73.2%) of irregular vaginal bleeding, 85 cases (41.5%) of hypertension, 69 cases (33.7%) of elevated fasting glucose and/or

diabetes, 97 cases (47.3%) of dyslipidemia, and 59 cases (28.8%) of metabolic syndrome. The control group had a mean age of 48.9 years, 77 cases of irregular vaginal bleeding (37.6%), 44 cases of hypertension (21.5%), 22 cases of elevated fasting glucose and/or diabetes (10.73%), 39 cases of dyslipidemia (19.02%), and 10 cases of metabolic syndrome (4.88%). Other basic conditions and metabolic parameters between patient groups are shown in Table 1.

Table 1
Baseline characteristics of patients.

Characteristics	n (%)			
	Study group (n = 205)	Control group (n = 205)	Total (n = 410)	P
Age				
≤ 50	103 (50.24)	82 (78.85)	185 (59.87)	
50–60	72 (35.12)	19 (18.27)	91 (29.45)	
≥60	30 (14.63)	3 (2.88)	33 (10.68)	
(mean ± SD)	49.42 ± 10.69	48.87 ± 10.60	49.15 ± 10.64	0.75
AUB				
Yes	150 (73.17)	77 (37.56)	227 (55.37)	
No	55 (26.83)	128 (62.44)	183 (44.63)	< 0.001
Menstrual Status				
menopause	83 (40.49)	46 (22.44)	186 (45.37)	
menstruating	122 (59.51)	159 (77.56)	224 (54.63)	< 0.001
Metabolic Characteristics				
BMI(kg/m ²)				
normal(BMI < 25)	76 (37.07)	147 (71.71)	223 (54.39)	
overweight (BMI ≥ 25)	129 (62.93)	58 (28.29)	187 (45.61)	< 0.001
SBP(mmHg)				
< 140	127 (61.95)	159 (77.56)	286 (69.76)	
≥ 140	78 (38.05)	46 (22.44)	124 (30.24)	0.001
DBP(mmHg)				
< 90	123 (60.00)	179 (87.32)	302 (73.66)	
≥ 90	82 (40.00)	26 (12.68)	108 (26.34)	< 0.001

Note: p < 0.05 (statistically significant).

Abbreviations: AUB, abnormal uterine bleeding. BMI, body mass index. SBP, systolic blood pressure; DBP, diastolic blood pressure. HBP, high blood pressure. CHO, total cholesterol, GLU, glucose. CEA, carcinoma embryonic antigen. TG, triglyceride. HDL, high-density lipoprotein. LDL, low-density lipoprotein. UA, uric acid. HLP, hyperlipidemia. MS, metabolic syndrome.

Characteristics	n (%)			
HBP				
Yes	85 (41.46)	44 (21.46)	129 (31.46)	
No	120 (58.54)	161 (78.54)	281 (68.54)	< 0.001
CHO (mmol/L)				
0-5.2	110 (53.66)	154 (75.12)	264 (64.39)	
> 5.2	95 (46.34)	51 (24.88)	146 (35.61)	< 0.001
GLU (mmol/L)				
≥ 5.5	69 (33.66)	22 (10.73)	91 (22.20)	
≤ 5.5	136 (66.34)	183 (89.27)	319 (77.80)	< 0.001
CEA (ug/L)				
0–5	203 (99.02)	203 (99.02)	406 (99.02)	
> 5	2 (0.98)	2 (0.98)	4 (0.98)	> 0.05
CA125 (U/ml)				
0-30.2	172 (83.90)	192 (93.66)	364 (88.78)	
> 30.2	33 (16.10)	13 (6.34)	46 (11.22)	0.002
CA199 (U/ml)				
0-30.9	162 (79.02)	194 (94.63)	356 (86.83)	
> 30.9	43 (20.98)	11 (5.37)	54 (13.17)	< 0.001
TG (mmol/L)				
0-1.7	134 (65.37)	180 (87.80)	314 (76.59)	
> 1.7	71 (34.63)	25 (12.20)	96 (23.41)	< 0.001
HDL (mmol/L)				
1.04–1.60	138 (67.32)	173 (81.73)	311 (75.85)	
< 1.04	67 (32.68)	32 (18.27)	99 (24.15)	< 0.001

Note: p < 0.05 (statistically significant).

Abbreviations: AUB, abnormal uterine bleeding. BMI, body mass index. SBP, systolic blood pressure; DBP, diastolic blood pressure. HBP, high blood pressure. CHO, total cholesterol, GLU, glucose. CEA, carcinoma embryonic antigen. TG, triglyceride. HDL, high-density lipoprotein. LDL, low-density lipoprotein. UA, uric acid. HLP, hyperlipidemia. MS, metabolic syndrome.

Characteristics	n (%)			
LDL (mmol/L)				
2.07–3.37	134 (65.37)	171 (83.41)	305 (74.39)	
> 3.37	71 (34.63)	34 (16.59)	105 (25.61)	< 0.001
UA (μmol/L)				
155–357	165 (80.49)	194 (94.63)	359 (87.56)	
> 357	40 (19.51)	11 (5.37)	51 (12.44)	< 0.001
HLP				
Yes	97 (47.32)	39 (19.02)	136 (33.17)	
No	108 (52.68)	166 (80.98)	274 (66.83)	< 0.001
MS				
Yes	59 (28.78)	10 (4.88)	69 (16.83)	
No	146 (71.22)	195 (95.12)	341 (83.17)	< 0.001
Note: p < 0.05 (statistically significant).				
Abbreviations: AUB, abnormal uterine bleeding. BMI, body mass index. SBP, systolic blood pressure; DBP, diastolic blood pressure. HBP, high blood pressure. CHO, total cholesterol, GLU, glucose. CEA, carcinoma embryonic antigen. TG, triglyceride. HDL, high-density lipoprotein. LDL, low-density lipoprotein. UA, uric acid. HLP, hyperlipidemia. MS, metabolic syndrome.				

Feature selection

Based on a retrospective analysis of the statistical characteristics of disease and treatment in 410 patients, six potential predictors were selected and generalized from 13 predictors associated with metabolic factors by comparing metabolic-related data in the case and control groups by single-factor logistic regression analysis. These potential predictors included hypertension, diabetes mellitus, BMI, hyperlipidemia, hyperuricemia, and CA199 (Table 2).

Table 2
Single-factor logistic regression of metabolic factor-related predictors

Variables	β	Odds ratio (95%CI)	P
Age	-0.029	0.971 (0.945–0.998)	0.037*
SBP	-0.022	0.978 (0.957–0.999)	0.039*
DBP	0.080	1.083 (1.046–1.122)	< 0.001*
FBG	0.563	1.756 (1.216–2.535)	0.003*
BMI	0.103	1.108 (1.028–1.194)	0.007*
CEA	0.150	1.162 (0.857–1.575)	0.335
CA125	0.005	1.005 (0.997–1.013)	0.248
CA199	0.032	1.033 (1.012–1.054)	0.002*
CHO	1.517	4.557 (1.882–11.038)	< 0.001*
TG	-0.315	0.730 (0.454–1.174)	0.195
HDL	-1.528	0.217 (0.062–0.759)	0.017*
LDL	-1.121	0.326 (0.133–0.798)	0.014*
UA	0.006	1.006 (1.002–1.010)	0.002*
Note: β is the regression coefficient. *p < 0.05 (statistically significant).			
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. FBG, fasting blood-glucose; BMI, body mass index; CEA, carcinoma embryonic antigen. TG, triglyceride. HDL, high-density lipoprotein. LDL, low-density lipoprotein. UA, uric acid.			

The results of multifactorial logistic regression analysis for hypertension, hyperglycemia, BMI > 25, hyperlipidemia, hyperuricemia, and CA199 are shown in Table 3. The BMI > 25 differences, hyperglycemia, hyperlipidemia, hyperuricemia, and CA199 between the study and control groups were statistically significant (P < 0.05). Another risk factor with a P value close to 0.05 or recognized in clinical and guideline settings, which is hypertension, was also considered as a metabolic risk factor associated with malignant endometrial hyperplasia in the present retrospective analysis. The above independent predictors were included in the Nomogram model (Fig. 1).

Table 3
Prediction factors for endometrial malignant hyperplasia.

Intercept and variable	Prediction model		
	β	Odds ratio (95%CI)	P
HBP	0.4594	1.583 (0.952–2.632)	0.076
HGlu	0.7711	2.162 (1.190–3.997)	0.012
BMI > 25	0.9069	2.477 (1.546–3.975)	< 0.001
HUA	1.0277	2.795 (1.330–6.252)	0.008
HLP	1.0204	2.774 (1.705–4.555)	< 0.001
CA199	1.4731	4.363 (2.120–9.634)	< 0.001
Note: β is the regression coefficient.			
Abbreviations: HBP, high blood pressure; HGlu, hyperglycemia; BMI, body mass index; HUA, hyperuricemia; HLP, hyperlipidemia; CA199: Carbohydrate antigen 199.			

In this study, we constructed and validated the above nomogram model based on six predictors, including blood pressure, blood glucose, blood lipids, BMI, uric acid, and CA199. These variables were selected based on the results of logistic regression analysis and risk factors highly associated with the risk of developing endometrial malignant hyperplasia as reported in previous studies. Patients can be scored for basic conditions such as metabolic indicators, and the scores are summed to obtain a total score that gives the corresponding predicted probability of developing endometrial malignant hyperplasia. The higher the score, the higher the probability of endometrial malignant hyperplasia. Therefore, clinicians can be reminded to identify the high-risk group of endometrial malignant hyperplasia from the perspective of glucose and lipid metabolism at an early stage, to develop standard methods for diagnosis and symptom assessment of high-risk patients, and to provide diagnosis and intervention at an early stage, such as controlling blood glucose, reasonable weight loss, regular health monitoring, etc., and to educate patients about symptoms and regular follow-up.

Apparent performance of the risk factors associated with endometrial malignant hyperplasia in the retrospective analysis

The calibration curves of the Nomogram model for predicting metabolic factors and risk of endometrial malignant hyperplasia showed good agreement in this retrospective analysis (Fig. 2). The C-index for predicting the risk of developing metabolic factors and endometrial malignancy was 0.782 (95% CI: 0.738–0.826) in this retrospective analysis. The Receiver Operating Characteristic (ROC, Receiver Operating Characteristic) curve for the Nomogram prediction model is shown in Fig. 3. area under the

curve AUC = 0.7816538. The corrected C-index of 0.771 is obtained after the Bootstrapping bootstrap validation of the model, which proves that the model has a good predictive ability.

Clinical use

The decision curve analysis of the Nomogram model for predicting the risk of developing metabolic factors and endometrial malignant hyperplasia is shown in Fig. 4. The decision curves show that when the threshold probability is between 22–86%, using this Nomogram line graph to predict the risk of developing metabolic factors and endometrial malignant hyperplasia, respectively, provides more benefit to the patient.

Discussion

Nomogram is now widely used in oncology and clinical medicine as a prediction and analysis tool for risk factors and prognosis. Nomogram relies on a user-friendly and easy-to-learn interface that can improve the accuracy of predictions and help clinicians make better clinical decisions. Our study is the first to apply Nomogram to risk factors related to gynecologic cancer and glycolipid metabolism, using six clinically accessible variables related to disease and treatment that are capable of initially predicting the risk of endometrial malignant hyperplasia in a metabolically abnormal population. This study provides a relatively accurate tool for predicting endometrial malignancy in women with metabolic disorders and contributes to the individualized prediction of patients' risk of developing endometrial malignant hyperplasia. Intra-group validation of the retrospective analysis showed good discrimination and calibration. In particular, there was still a high C-index when the model was validated by bootstrapping, indicating that the retrospective analysis had a large sample size and was widely used, generalizable and accurate in practice.

Metabolic syndrome is a complex disorder in which insulin resistance, hyperinsulinemia, impaired glucose tolerance, type 2 diabetes mellitus, dyslipidemia and visceral obesity are a series of risk factors associated with the development of metabolic syndrome^[3]. Endometrial cancer is one of the cancers most closely associated with metabolic diseases, and the incidence of endometrial cancer is increasing as the incidence of metabolic diseases increases^[7]. Endometrial atypical hyperplasia is also strongly associated with metabolic factors^[8]. A meta-analysis by Esposito et al showed that the metabolic syndrome is strongly associated with an increased risk of endometrial cancer^[9]. Kitson et al reported that women diagnosed with endometrial cancer had a higher incidence of metabolic abnormalities than women without endometrial cancer^[10]. In this retrospective analysis, age, hypertension, diabetes mellitus, BMI, hyperlipidemia, and blood uric acid were associated with the development of endometrial malignancy in patients. Of these, obesity, diabetes and hypertension are commonly referred to as the metabolic triad of endometrial cancer. In recent years, several studies have shown that the metabolic syndrome caused by obesity, diabetes and hypertension is closely associated with the incidence and poor

prognosis of endometrial cancer. It has been shown that patients with hyperglycemia, hyperlipidemia and hypertension are twice as likely to develop endometrial cancer as normal people^[11]. The aim of this study was to investigate the association of metabolic factors with endometrial atypical hyperplasia and endometrial cancer. This study is also the first to identify a potential link between high uric acid and endometrial malignancy. The exact mechanisms by which metabolic syndrome affects the development of endometrial lesions are complex and may be related to the following.

Obesity and endometrial cancer

Adipose tissue is an important endocrine organ that secretes a variety of hormones such as leptin and lipofuscin, as well as chemokines that modulate tumor behavior, inflammation, and the tumor microenvironment^[12]. The excessive accumulation of adipose tissue in obese patients leads to increased levels of free fatty acids in the circulatory system and increased expression of serum adipokines (e.g., leptin, endolipoproteins, and cytokines), which ultimately leads to insulin resistance. Among these, decreased serum adiponectin levels and increased chronic inflammation in obese patients are important factors that increase the risk of endometrial cancer. Over-expansion of fat in obese patients leads to adipose dysfunction and inflammation, thereby increasing the levels of pro-inflammatory factors throughout the body^[13]. Chronic inflammation also lays the groundwork for the cancer development band. This inflammatory response also contributes to the increased prevalence and mortality of endometrial cancer associated with obesity. Obesity may also increase the risk of endometrial cancer by indirectly affecting estrogen levels^[14]. Obesity-induced insulin resistance leads to hyperinsulinemia, which may reduce the synthesis of sex hormone-binding protein (SHBG) by increasing the bioavailability of insulin-like growth factor-1 (IGF-1), resulting in elevated estrogen levels. Adipose tissue-derived aromatase also converts androstenedione to estradiol, resulting in elevated serum estradiol levels, estradiol binding to estrogen receptors, and ultimately, transcription factor recruitment, and gene transcription may be activated or inhibited^[12, 15]. Ward et al reported that people with a history of bariatric surgery and those who were able to maintain a normal weight after surgery were able to reduce their risk of uterine malignancy by 71% and 81%, respectively^[16]. These studies show a close relationship between obesity and the development of endometrial cancer.

Hyperglycemia and endometrial cancer

Diabetes mellitus is a risk factor for endometrial cancer. Patients with type 2 diabetes mellitus are often associated with hyperinsulinemia and insulin resistance. In a state of insulin resistance, elevated insulin levels directly or indirectly influence the development of endometrial cancer^[17]. Direct mechanisms include the activation of key signaling pathways such as PI3K/Akt, Ras/MAPK; and the interaction of signaling pathways between insulin, IGF-1, and estrogen. Among the indirect mechanisms, excess insulin leads to decreased blood levels of sex hormone-binding protein (SHBG) and increased blood levels of estrogen and androgen, thereby promoting the development of endometrial cancer^[18]. It has been shown that serum insulin levels can increase the incidence of endometrial cancer in a dose-dependent manner. Also insulin resistance is a key pathophysiological process in obesity, diabetes, hypertension and even

metabolic syndrome. In addition, diabetic patients in a high glucose state can promote the proliferation and invasion of endometrial cancer cells by regulating the expression of ER α /Glut4, which promotes the expression of vascular endothelial growth factor/vascular endothelial growth factor receptor^[19]. In addition, high glucose also increases glucose uptake and glycolytic activity by modulating AMPK/mTOR/S6 and MAPK signaling pathways, thereby increasing the invasiveness of endometrial cancer cells^[20].

Most of the epidemiological evidence also suggests that diabetes is a risk factor for the development of endometrial lesions. A meta-analysis of 16 studies by Friberg et al showed that diabetes was statistically significantly associated with an increased risk of endometrial cancer (RR 2.10, 95% CI 1.75–2.53)^[21]. Diabetes not only increases the incidence of endometrial cancer, but also increases the relative risk of death in endometrial cancer patients. Epidemiological studies have shown that the risk of endometrial cancer is 2.12 times higher in diabetic patients and 2.45 times higher in overweight patients than in normal patients^[22]. type 2 diabetes combined with obesity significantly increases the risk of endometrial cancer^[17].

Dyslipidemia and endometrial cancer

There are more studies on the relationship between endometrial cancer and obesity and diabetes mellitus, but fewer studies on the relationship between endometrial cancer and hypertension and dyslipidemia. Abnormal lipid metabolism, especially elevated free fatty acids, is strongly associated with the progression of endometrial cancer^[23]. The possible mechanisms of dyslipidemia associated with endometrial cancer risk are: activation of the fatty acid and aminoglycan pathways leads to the production of reactive oxygen species (ROS) in mitochondria, causing cellular oxidative stress; excessive accumulation of ROS clusters, which interact with intracellular lipids, proteins, and DNA, leads to altered cell membrane and enzyme function, inducing cellular damage and ultimately tumorigenesis^[24]. In addition, serum cholesterol is elevated in obese patients, and cholesterol activates the transcriptional activity of endometrial cancer cells through an ER-dependent pathway, which promotes the proliferation of endometrial cancer cells^[25].

Other relevant doctrines and endometrial cancer

A meta-analysis by Aune et al showed that hypertension is a risk factor for endometrial cancer^[26]. A large cohort study of 290,000 women found that the risk of endometrial cancer increased with increasing blood pressure levels, particularly systolic blood pressure levels^[27]. However, because hypertension is a condition that is closely related to lifestyle factors and a number of medical conditions (including diet, BMI, physical activity, and diabetes), there are still definite limitations to the current study. The biological mechanism by which hypertension increases the risk of endometrial cancer is unclear and may be related to cellular senescence and apoptosis inhibition caused by chronic hypertension.

Serum uric acid (SUA) is an antioxidant that is abundant in the blood and plays an important role as a free radical scavenger, and has been linked to many lifestyle-related diseases such as metabolic syndrome and type 2 diabetes^[28, 29]. Numerous in vitro and animal studies suggest that the relationship between SUA metabolism and oxidative stress may be involved in the onset and/or development of disease. Epidemiological investigations have shown that individuals with higher uric acid levels may have a higher incidence of cancer. A large prospective study of 28,613 older women showed that elevated uric acid (> 5.41 mg/dL) was independently associated with an increased risk of death from all cancer types^[30, 31].

In addition, dynamic interactions between cells and their microenvironment play an important role in regulating the growth of normal tissues and cancer cells^[32]. The tumor cell microenvironment includes tumor cells and other cells, such as fibroblasts, lymphocytes, macrophages, adipocytes, and other secretory factors. An abnormal imbalance in the tumor cell microenvironment often leads to tumorigenesis. This also suggests that the metabolic syndrome and its associated signaling molecules can not only act directly on tumor cells, but also further remodel the tumor immune microenvironment, thereby accelerating the progression of endometrial cancer^[33].

Limitations

Our current study also has some limitations. First, this retrospective analysis does not represent all Chinese patients with endometrial lesions. Patients with no access to treatment were also excluded from this retrospective analysis. Second, the risk factors included in this study did not include all the potential risk factors that influence the development of metabolic factors and endometrial lesions. Third, although the Nomogram model for this retrospective analysis has been extensively tested by bootstrapping, it has not been possible to externally validate this model and there is uncertainty about its generalizability to other endometrial lesion populations in other regions and countries. It needs to be externally evaluated in a broader endometrial lesion population.

Conclusion

Our study revealed the correlation between hypertension, hyperglycemia, BMI > 25, hyperlipidemia, hyperuricemia, CA199 and endometrial malignant hyperplasia based on the retrospective analysis of metabolic-related factors in 410 patients. Among them, CA199 is a tumor marker closely related to endometrial cancer^[34]. Hypertension, diabetes mellitus, BMI > 25, hyperlipidemia, hyperuricemia and high CA199 index are all high-risk factors for endometrial malignant hyperplasia, and the probability of endometrial malignant hyperplasia will be greatly increased in patients with multiple high-risk factors. This study also establishes a new Nomogram model with good accuracy to develop an effective tool for predicting the risk of endometrial malignancy in women with metabolic-related risk factors. Previous scientific studies have provided effective therapeutic targets for the treatment of endometrial cancer based on the relationship between metabolic syndrome and cancer, but lifestyle improvement and early

intervention remain the most important components of preventing morbidity and mortality from metabolic syndrome-associated endometrial cancer. This model provides clinicians with the necessary assistance in identifying and predicting a patient's risk of developing endometrial malignant growth at an early stage based on their metabolic profile. By estimating the risk of the disease, clinicians and patients can take more adequate and necessary measures in terms of lifestyle monitoring and medical interventions.

In addition, the model can be used as a tool for screening patients at high risk for endometrial lesions in clinical studies. For example, the model could be used to select reliable patients with good adherence to medications in prospective controlled studies. In retrospective studies, we could also exclude patients with poor adherence, thus making the analysis more reliable. This Nomogram model still needs to be externally validated to make the predictive power broad and generalizable. In the meantime, further studies will be conducted to determine whether individual interventions based on the Nomogram model can reduce the risk of endometrial malignant hyperplasia in women with metabolism-related risk factors.

Declarations

Acknowledgments

We appreciate the effort of the physicians for enrolling patients and thank all the patients involved for allowing us to analyze their clinical data.

Author contributions

HZ, WK, DS contributed to project development, data collection, and manuscript writing; JL involved in imaging data analysis; TL involved in pathological data analysis; CH involved in project development and manuscript editing. All the authors participated in discussion and revision of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and informed consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Science and Technology Division of Beijing Obstetrics and Gynecology Hospital, Capital Medical University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

- [1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. *CA Cancer J Clin*, 2020, 70(1): 7-30. doi:10.3322/caac.21590.
- [2] Sanderson P A, Critchley H O, Williams A R, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia[J]. *Hum Reprod Update*, 2017, 23(2): 232-254. doi:10.1093/humupd/dmw042.
- [3] Eckel R H, Grundy S M, Zimmet P Z. The metabolic syndrome[J]. *Lancet*, 2005, 365(9468): 1415-28. doi:10.1016/s0140-6736(05)66378-7.
- [4] Shou H, Yan K, Song J, et al. Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus[J]. *Int J Gynaecol Obstet*, 2020, 148(1): 96-101. doi:10.1002/ijgo.12984.
- [5] The Use of Hysteroscopy for the Diagnosis and Treatment of Intrauterine Pathology: ACOG Committee Opinion, Number 800[J]. *Obstet Gynecol*, 2020, 135(3): e138-e148. doi:10.1097/aog.0000000000003712.
- [6] Yen C F, Chou H H, Wu H M, et al. Effectiveness and appropriateness in the application of office hysteroscopy[J]. *J Formos Med Assoc*, 2019, 118(11): 1480-1487. doi:10.1016/j.jfma.2018.12.012.
- [7] Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. *Lancet*, 2016, 387(10023): 1094-1108. doi:10.1016/s0140-6736(15)00130-0.
- [8] Raffone A, Travaglino A, Saccone G, et al. Diabetes Mellitus Is Associated with Occult Cancer in Endometrial Hyperplasia[J]. *Pathol Oncol Res*, 2020, 26(3): 1377-1384. doi:10.1007/s12253-019-00684-3.
- [9] Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis[J]. *Diabetes Care*, 2012, 35(11): 2402-11. doi:10.2337/dc12-0336.
- [10] Kitson S J, Lindsay J, Sivalingam V N, et al. The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study[J]. *Gynecol Oncol*, 2018, 148(1): 154-160. doi:10.1016/j.ygyno.2017.11.019.
- [11] Arthur R S, Kabat G C, Kim M Y, et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study[J]. *Cancer Causes Control*, 2019, 30(4): 355-363. doi:10.1007/s10552-019-01139-5.
- [12] Deng T, Lyon C J, Bergin S, et al. Obesity, Inflammation, and Cancer[J]. *Annu Rev Pathol*, 2016, 11: 421-49. doi:10.1146/annurev-pathol-012615-044359.
- [13] Secord A A, Hasselblad V, Von Gruenigen V E, et al. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis[J]. *Gynecol Oncol*, 2016, 140(1): 184-90. doi:10.1016/j.ygyno.2015.10.020.

- [14] Sung H, Siegel R L, Torre L A, et al. Global patterns in excess body weight and the associated cancer burden[J]. *CA Cancer J Clin*, 2019, 69(2): 88-112. doi:10.3322/caac.21499.
- [15] Roque D R, Makowski L, Chen T H, et al. Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project[J]. *Gynecol Oncol*, 2016, 142(2): 317-22. doi:10.1016/j.ygyno.2016.06.006.
- [16] Ward K K, Roncancio A M, Shah N R, et al. Bariatric surgery decreases the risk of uterine malignancy[J]. *Gynecol Oncol*, 2014, 133(1): 63-6. doi:10.1016/j.ygyno.2013.11.012.
- [17] Lai Y, Sun C. Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer[J]. *Oncol Lett*, 2018, 15(2): 2173-2178. doi:10.3892/ol.2017.7590.
- [18] Mu N, Zhu Y, Wang Y, et al. Insulin resistance: a significant risk factor of endometrial cancer[J]. *Gynecol Oncol*, 2012, 125(3): 751-7. doi:10.1016/j.ygyno.2012.03.032.
- [19] Gu C J, Xie F, Zhang B, et al. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion[J]. *Cell Physiol Biochem*, 2018, 50(2): 706-720. doi:10.1159/000494237.
- [20] Wallbillich J J, Josyula S, Saini U, et al. High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer[J]. *PLoS One*, 2017, 12(1): e0170318. doi:10.1371/journal.pone.0170318.
- [21] Friberg E, Orsini N, Mantzoros C S, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis[J]. *Diabetologia*, 2007, 50(7): 1365-74. doi:10.1007/s00125-007-0681-5.
- [22] Yang X, Wang J. The Role of Metabolic Syndrome in Endometrial Cancer: A Review[J]. *Front Oncol*, 2019, 9: 744. doi:10.3389/fonc.2019.00744.
- [23] Madak-Erdogan Z, Band S, Zhao Y C, et al. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling[J]. *Cancer Res*, 2019, 79(10): 2494-2510. doi:10.1158/0008-5472.Can-18-2849.
- [24] Schmandt R E, Iglesias D A, Co N N, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention[J]. *Am J Obstet Gynecol*, 2011, 205(6): 518-25. doi:10.1016/j.ajog.2011.05.042.
- [25] Gibson D A, Collins F, Cousins F L, et al. The impact of 27-hydroxycholesterol on endometrial cancer proliferation[J]. *Endocr Relat Cancer*, 2018, 25(4): 381-391. doi:10.1530/erc-17-0449.
- [26] Aune D, Sen A, Vatten L J. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies[J]. *Sci Rep*, 2017, 7: 44808. doi:10.1038/srep44808.

- [27] Bjørge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma[J]. *Am J Epidemiol*, 2010, 171(8): 892-902. doi:10.1093/aje/kwq006.
- [28] Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis[J]. *Eur J Cancer Prev*, 2018, 27(4): 399-405. doi:10.1097/cej.0000000000000440.
- [29] Yang J, Wang Y, Zhao Q, et al. Association of serum uric acid with increased risk of cancer among hypertensive Chinese[J]. *Int J Cancer*, 2017, 141(1): 112-120. doi:10.1002/ijc.30731.
- [30] Kühn T, Sookthai D, Graf M E, et al. Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study[J]. *Br J Cancer*, 2017, 117(10): 1572-1579. doi:10.1038/bjc.2017.313.
- [31] Yiu A, Van Hemelrijck M, Garmo H, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study[J]. *Oncotarget*, 2017, 8(26): 42332-42342. doi:10.18632/oncotarget.16198.
- [32] Deberardinis R J. Tumor Microenvironment, Metabolism, and Immunotherapy[J]. *N Engl J Med*, 2020, 382(9): 869-871. doi:10.1056/NEJMcibr1914890.
- [33] Iyengar N M, Gucalp A, Dannenberg A J, et al. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation[J]. *J Clin Oncol*, 2016, 34(35): 4270-4276. doi:10.1200/jco.2016.67.4283.
- [34] Hutt S, Tailor A, Ellis P, et al. The role of biomarkers in endometrial cancer and hyperplasia: a literature review[J]. *Acta Oncol*, 2019, 58(3): 342-352. doi:10.1080/0284186x.2018.1540886.

Figures




Figure 1

Nomogram prediction model for the risk of developing endometrial malignant hyperplasia. Notes: The endometrial malignant hyperplasia nomogram prediction models were developed in this retrospective analysis, with HUA, HBP, BMI, HLP, HGLu, CA199. Abbreviations: HUA: hyperuricemia; HBP: hypertension; BMI: body mass index; HLP: hyperlipidemia; HGLu: hyperglycemia; CA199: Carbohydrate antigen 199.




Figure 2

The Nomogram prediction model of this retrospective analysis of calibration curves. Notes: The x-axis indicates the predicted endometrial malignant hyperplasia risk. The y-axis indicates the actual diagnosed endometrial malignant hyperplasia risk. The diagonal dotted line represents a perfect prediction by an ideal model. The solid line represents the performance of the nomogram, of which a closer fit to the diagonal dotted line represents a better prediction




Figure 3

ROC curves for the Nomogram predictive model. Notes: The vertical axis indicates the True Positive Rate (TPR) and the horizontal axis indicates the False Positive Rate (FPR). The area under the curve AUC = 0.7816538.




Figure 4

Decision curve analysis for the nomogram prediction model. Notes: The y-axis measures the net benefit. The dotted line represents the endometrial malignant hyperplasia risk nomogram. The thin solid line represents the hypothesis that all patients do not receive the intervention. A thick solid line indicates that no patient has a relevant metabolic factor disease. The decision curves show that it is meaningful to use this Nomogram to predict patients' risk of morbidity and intervene on treatment when the threshold probability is within 22-86%.